Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
August 13, 2008

Sanofi-Aventis Expands Collaboration with ImmunoGen for $3.5M

  • Sanofi-aventis has increased its access to ImmunoGen’s Tumor-Activated Prodrug (TAP) technology. The expansion earned ImmuGen $3.5 million.

    The agreement now extends until August 31, 2011 and can be renewed by sanofi-aventis for one additional three-year term through the payment of a $2 million fee.
    ImmunoGen is entitled to earn upfront and milestone payments potentially totaling $32 million per target for each compound developed under the 2006 agreement as well as royalties on commercial sales. ImmunoGen also is entitled to manufacturing payments for any materials made on behalf of sanofi-aventis.

    Expansion of the collaboration was an option granted under a 2006 agreement. Excercising the option enables sanofi-aventis to evaluate, with certain restrictions, the maytansinoid TAP technology with antibodies to targets not included in the existing research collaboration between the companies. It also allows the firm to license the exclusive right to use the technology to develop products to specific targets on the terms in the 2006 agreement.